Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL-HIV trial: DATASET by Sculier, Delphine et al.
 
 
 
Faculty of Medicine 
 
Institutes of Social & Preventive 
Medicine (ISPM), Primary Health 
Care (BIHAM) and CTU 
 
 
 
 
Bern, Oct 8, 2020 
 
DATASET: 
 
Study title:  
 
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 
suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL-HIV trial 
 
 
Authors: 
Delphine Sculier1,2, Gilles Wandeler3,4, Sabine Yerly5, Annalisa Marinosci1, Marcel Stoeckle6, Enos 
Bernasconi7, Dominique L. Braun8,9, Pietro Vernazza10, Matthias Cavassini11, Marta Buzzi1, Karin J. 
Metzner8,9, Laurent Decosterd12, Huldrych F. Günthard8,9, Patrick Schmid10, Andreas Limacher13, Matthias 
Egger4,14,15, and Alexandra Calmy1; and the Swiss HIV Cohort Study 
 
1 HIV/AIDS Unit, Department of Infectious Diseases, Geneva University Hospitals and the University of Geneva Faculty of Medicine, 
Geneva, Switzerland  
2 Private Practice Office, Geneva, Switzerland 
3 Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland 
4 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland 
5 Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland 
6 Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, University of Basel, Switzerland 
7 Service of Infectious Diseases, Lugano Regional Hospital, Lugano, Switzerland 
8 Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland 
9 Institute of Medical Virology, University of Zurich, Zurich, Switzerland 
10 Division of Infectious Diseases and Hospital Epidemiology, Kantonspital St.Gallen, St. Gallen, Switzerland 
11 Department of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland 
12 Pharmacology Laboratory, Clinical Pharmacology Department, University of Lausanne, Lausanne, Switzerland 
13 CTU Bern, University of Bern, Bern, Switzerland  
14 Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa 
15 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK 
 
 
The dataset containing the files underlying the study manuscript will be made available upon request and after signing a 
data transfer agreement. Additional relevant documentation will be made publicly available under a cc-by license upon 
publication. 
 
 
For data request and further information, please contact: 
CTU Bern, University of Bern 
datarequest@ctu.unibe.ch   
 
 
 s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
6
8
0
8
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
